Press

Select publications and latest media
  • Press Release

    JUL 2020

    Excision BioTherapeutics to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit

  • FierceBiotech

    JUN 2020

    Biopharma tackles COVID-19, HIV and other viruses with gene and cell therapies

  • NATURE BRIEFING

    MAY 2020

    Gene-Editing Pipeline Takes Off

    --

    Clinical trials of genome-editing agents — including CRISPR–Cas9 editors, zinc finger nucleases and TALENs — are pushing ex vivo, immuno-oncology and in vivo treatment frontiers.

  • PRESS RELEASE

    MAR 2020

    Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination

  • PRESS RELEASE

    DEC 2019

    CRISPR-focused Excision Bio Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D.

  • PRESS RELEASE

    NOV 2019

    CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure

  • PRESS RELEASE

    NOV 2019

    Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology

  • PRESS RELEASE

    JUL 2019

    HIV Eliminated from the Genomes of Living Animals; Excision BioTherapeutics Advancing the Innovation to Clinical Development

  • NATURE COMMUNICATIONS

    JUL 2019

    Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected  Humanized Mice

  • PRESS RELEASE

    JUL 2019

    Enlisting CRISPR in the Quest for an HIV Cure

  • SCIENTIFIC REPORTS

    JAN 2019

    Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection

  • FRONTIERS IN MICROBIOLOGY

    DEC 2018

    Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection

  • AIDS RES HUM RETROVIRUS

    NOV 2018

    Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics


     

  • AIDS REVIEW

    OCT 2018

    Toward the cure of HIV-1 infection: lessons learned and yet to be learned as new strategies are developed

  • MOL THER NUCLEIC ACIDS

    JUN 2018

    Removal of HIV DNA by CRISPR from Patient Blood Engrafts in Humanized Mice

  • PRESS RELEASE

    NOV 2017

    Excision BioTherapeutics Exclusively Licenses New CRISPR-Cas Gene Editors from UC Berkeley to be Used for Viral Infections

  • J CELL BIOCHEM

    NOV 2017

    CRISPR editing technology in biological and biomedical investigation

  • PRESS RELEASE

    SEP 2017

    HIV Cure-Focused Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures

  • CELL MOL LIFE SCI

    JUL 2017

    Novel AIDS therapies based on gene editing

  • MOLECULAR THERAPY

    MAY 2017

    In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models

  • PLOS PATHOGENS

    DEC 2016

    Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape

  • GENE THERAPY

    AUG 2016

    Excision of HIV-1 DNA by Gene Editing: A Proof-of-Concept In Vivo Study

  • SCIENTIFIC REPORTS

    AUG 2016

    Negative Feedback Regulation of HIV-1 by Gene Editing Strategy

  • SCIENTIFIC REPORTS

    APR 2016

    Inhibition of HSV-1 Replication by Gene Editing Strategy

  • SCIENTIFIC REPORTS

    MAR 2016

    Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/ Cas9 Gene Editing

  • PRESS RELEASE

    MAR 2016

    Use of CRISPR Cas9 Gene Editing Therapeutic Shown to Permanently Inactivate HIV-1 in Patient’s Blood for First Time

  • J CELL PHYSIOLOGY

    DEC 2015

    Animal Models for Progressive Multifocal Leukoencephalopathy

  • PLOS ONE

    SEP 2015

    CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection

  • J NEUROVIROL

    FEB 2015

    Genome editing strategies: potential tools for eradicating HIV-1/AIDS

  • PROC NATL ACAD SCIENCES

    JUN 2014

    RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection

988 Market Street
San Francisco, CA 94102
USA

1755 N. 13th Street #274
Philadelphia, PA 19122
USA

© 2020 Excision BioTherapeutics. All Rights Reserved.